🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 47 of 173

  1. US 10791731

    Methods for preparing frozen plasma material for rapid thawing in an emergency situation

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10786495

    Vesicular monoamine transporter 2 inhibitors for treating stuttering

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10787499

    EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10787439

    Compounds and methods for activating the apoptotic arm of the unfolded protein response

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10780145

    In situ forming hydrogel and method using same

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10781208

    5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10780136

    Reduction of milk glycans and their degradation products in the neonate gut

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10781183

    Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10780133

    Method for protecting liver and a liver protecting agent

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10781422

    Compositions and methods for treating retinal diseases

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10781255

    Anti-CD83 antibodies and use thereof

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10781218

    Substituted inhibitors of menin-MLL and methods of use

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10780155

    Streptococcal GlcNac-lacking gylcopolypeptides, cell wall carbohydrates, Streptococcus vaccines, and methods for making and using them

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10780095

    Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10779517

    Animal wound model and methods of use

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10780078

    Mu opioid receptor modulators

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10780131

    Ameliorating nervous systems disorders

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10774118

    Peptides having reduced toxicity that stimulate cholesterol efflux

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10774121

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10774122

    ERG targeted therapy

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10774056

    Substituted piperazines as selective HDAC1,2 inhibitors

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10772913

    Administration of kynurenine depleting enzymes for tumor therapy

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10772828

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10772861

    Administration of serine protease inhibitors to the stomach

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10774334

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10772911

    Cell free compositions for cellular restoration and methods of making and using same

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10772333

    Mollusk-killing biopesticide

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10772504

    Apparatus, systems and methods for intraoperative imaging

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10774344

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10774390

    Methods and compositions for modulating PrfA mediated virulence gene activation in Listeria spp

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10765745

    Multifunctional nanoparticle systems and methods for cancer diagnosis and combination therapy

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10767179

    MicroRNA composition for the treatment of neuroblastoma

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10766892

    GLS1 inhibitors for treating disease

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10768167

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10765776

    Tissue-derived biomaterial composition and methods for ocular and other therapeutic applications

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10766927

    Peptides that stimulate subcutaneous adipogenesis

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10766925

    Opioid receptor modulators

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10766908

    Calcium L-lactate frameworks as naturally degradable carriers

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10765636

    Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10765759

    Methods of treating an ocular disease or disorder

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10759774

    Inhibitors of hepatitis B virus targeting capsid assembly

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10758619

    Controlled release mucoadhesive systems

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10758511

    Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10760048

    In vitro production of medial ganglionic eminence precursor cells

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10760055

    Conditionally immortalized long-term stem cells and methods of making and using such cells

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10758632

    NIR-conjugated tumor-specific antibodies and uses thereof

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10758600

    Fungal immunogens and related materials and methods

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10759839

    Cell-penetrating peptide

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.